Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) EPS (Weighted Average and Diluted) (2020 - 2025)

X4 Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at $1.0 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 116.84% year-over-year to $1.0; the TTM value through Dec 2025 reached -$3.12, up 44.48%, while the annual FY2025 figure was -$1.87, 66.55% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $1.0 in Q4 2025 per XFOR's latest filing, up from -$0.69 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $13.57 in Q2 2024 to a low of -$16.59 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$1.65, with a median of -$0.64 recorded in 2025.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 4212.12% in 2024 against a maximum downside of 54700.0% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.28 in 2021, then skyrocketed by 84.38% to -$0.2 in 2022, then crashed by 8195.0% to -$16.59 in 2023, then soared by 64.2% to -$5.94 in 2024, then skyrocketed by 116.84% to $1.0 in 2025.
  • Per Business Quant, the three most recent readings for XFOR's EPS (Weighted Average and Diluted) are $1.0 (Q4 2025), -$0.69 (Q3 2025), and -$3.47 (Q2 2025).